Title

Prostaglandin E(2) and myocarditis; friend or foe?

Authors

Timothy D. Bryson, Henry Ford HealthFollow
Pamela Harding, Henry Ford HealthFollow

Recommended Citation

Bryson TD, and Harding P. Prostaglandin E(2) and myocarditis; friend or foe? Biochem Pharmacol 2023; 217:115813.

Document Type

Article

Publication Date

11-1-2023

Publication Title

Biochemical pharmacology

Abstract

This review article summarizes the role of prostaglandin E(2) (PGE(2)) and its receptors (EP1-EP4) as it relates to the inflammatory cardiomyopathy, myocarditis. During the COVID-19 pandemic, the onset of myocarditis in a subset of patients prompted a debate on the use of nonsteroidal anti-inflammatory drugs (NSAIDs), like ibuprofen, which act to inhibit the actions of prostaglandins. This review aims to further understanding of the role of PGE(2) in the pathogenesis or protection of the myocardium in myocarditis. Inflammatory cardiomyopathies encompass a broad spectrum of disorders, all characterized by cardiac inflammation. Therefore, for the purpose of this review, the authors have placed particular emphasis on etiologies of myocarditis where effects of PGE(2) have been documented.

Medical Subject Headings

Humans; Myocarditis; Pandemics; Receptors, Prostaglandin E, EP4 Subtype; Dinoprostone; Prostaglandins

PubMed ID

37722627

Volume

217

First Page

115813

Last Page

115813